The fact that interferon-α (IFN-α) impacts on AML through immune activation (20, 21) has rekindled the interest in the utility of IFN-α in AML patients following allo-HSCT as an immunotherapeutic option (22–26). This evidence concerns the gene IFNA2 and acute myeloid leukemia.